Simulations Plus, Inc. provides model-informed and AI-accelerated drug development software, training, and consulting services for biopharmaceutical research. News about the company centers on its software and services segments, scientific modeling engines, ADMET and other modeling workflows, and financial results tied to software renewals, services bookings, and customer activity.
Recurring developments also include collaborations with pharmaceutical companies, technology providers, and regulatory or public-health agencies. These updates cover GPU-accelerated simulation, AI-assisted modeling, predictive frameworks for complex oral drug products, computational toxicology, new approach methodologies, and education programs that expand use of model-informed drug development practices.
Simulations Plus (NASDAQ: SLP) has accelerated the second phase of its collaboration with a major pharmaceutical firm to enhance its high-throughput pharmacokinetic (HTPK) simulation capabilities within ADMET Predictor®. This collaboration follows positive feedback from the first phase and aims to improve lead selection for small molecule programs. The company emphasizes the benefits of tailored functionalities for its partner, which will enhance research timelines and medication development for patients.